Volume 35, Issue 6 (September 2024)
Studies in Medical Sciences 2024, 35(6): 492-501 |
Back to browse issues page
Ethics code: IR.UMSU.REC.1398.416
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Azemoodeh M, Shirpoor A, Rasmi Y, Fathi Azarbayjani A. DEVELOPMENT AND EVALUATION OF NOVEL PIOGLITAZONE DRUG DELIVERY SYSTEM IN DIABETIC WISTAR RAT MODEL. Studies in Medical Sciences 2024; 35 (6) :492-501
URL: http://umj.umsu.ac.ir/article-1-6256-en.html
URL: http://umj.umsu.ac.ir/article-1-6256-en.html
Urmia University of Medical Sciences , anahita@u.nus.edu
Abstract: (182 Views)
Abstract
Background & Aims: Diabetes is a metabolic disorder characterized by high blood glucose levels and insulin resistance. Pioglitazone can lower insulin resistance and has anti-inflammatory properties. The aim of this work was to develop pioglitazone-loaded nanofibers and to evaluate their effect as a dermal implant device to lower blood glucose levels. The effect of pioglitazone-loaded nanofiber was investigated as a wound dressing in diabetic Wistar rats.
Materials & Methods: In this work, nanofibers were developed using the electrospinning method. The structure and characteristics of the fibers were evaluated using scanning electron microscopy and Fourier Transform Infrared Spectroscopy. The effect of nanofiber implants was evaluated on blood glucose levels , and their wound healing effect was investigated in diabetic wounds in a Wistar rat model.
Results: The developed formulations did not show any effect in lowering blood glucose when used as an implant; however, they were able to accelerate the wound healing rate when used as a dressing in the wound model. This effect might be due to the anti-inflammatory properties of the drug. The developed wound dressing was able to accelerate the formation of the epidermis and dermis layers in the wound model.
Conclusion: Histological studies indicate that wounds treated with pioglitazone-loaded nanofibers exhibit an anti-inflammatory effect and therefore can increase the wound healing rate. These drug-loaded nanofibers enhanced the development of collagen and improved the formation of the epidermis and dermis while reducing the number of inflammatory cells. The developed drug delivery system was not able to significantly decrease blood glucose levels in the animal model. This effect may be due to the low drug loading capacity as well as its poor aqueous solubility.
Background & Aims: Diabetes is a metabolic disorder characterized by high blood glucose levels and insulin resistance. Pioglitazone can lower insulin resistance and has anti-inflammatory properties. The aim of this work was to develop pioglitazone-loaded nanofibers and to evaluate their effect as a dermal implant device to lower blood glucose levels. The effect of pioglitazone-loaded nanofiber was investigated as a wound dressing in diabetic Wistar rats.
Materials & Methods: In this work, nanofibers were developed using the electrospinning method. The structure and characteristics of the fibers were evaluated using scanning electron microscopy and Fourier Transform Infrared Spectroscopy. The effect of nanofiber implants was evaluated on blood glucose levels , and their wound healing effect was investigated in diabetic wounds in a Wistar rat model.
Results: The developed formulations did not show any effect in lowering blood glucose when used as an implant; however, they were able to accelerate the wound healing rate when used as a dressing in the wound model. This effect might be due to the anti-inflammatory properties of the drug. The developed wound dressing was able to accelerate the formation of the epidermis and dermis layers in the wound model.
Conclusion: Histological studies indicate that wounds treated with pioglitazone-loaded nanofibers exhibit an anti-inflammatory effect and therefore can increase the wound healing rate. These drug-loaded nanofibers enhanced the development of collagen and improved the formation of the epidermis and dermis while reducing the number of inflammatory cells. The developed drug delivery system was not able to significantly decrease blood glucose levels in the animal model. This effect may be due to the low drug loading capacity as well as its poor aqueous solubility.
Keywords: Nanofiber, Electrospinning, Pioglitazone, Dermal implant, glucose, wound healing, diabetes, anti-inflammatory
Type of Study: Research |
Subject:
فارماکولوژی
References
1. Patil S, Pawar A, Kumar Sahoo S, Effect of additives on the physicochemical and drug release properties of pioglitazone hydrochloride spherical agglomerates. Trop J Pharm Res 2012;11(1): 18-27. [URL:] [DOI:10.4314/tjpr.v11i1.3]
2. Strongman H, Korhonen P, Williams R, Bahmanyar S, Hoti F, Christopher S, et al. Pioglitazone and risk of mortality in patients with type-2 diabetes: results from a european multidatabase cohort study. BMJ Open Diabetes Res Care 2017; 5(1): e000364. [PMID: 28761650] [DOI:10.1136/bmjdrc-2016-000364] [PMCID: PMC5530248]
3. Shah P, Mudaliar S, Pioglitazone: Side effect and safety profile. Expert Opin Drug Saf 2010; 9(2): 347-354. [PMID: 20175701] [DOI:10.1517/14740331003623218]
4. Nair AB, Gupta S, Al-Dhubiab BE, Jacob S, Shinu P, Shah J, et al. Effective therapeutic delivery and Bioavailability enhancement of pioglitazone using drug in adhesive transdermal patch, Pharmaceutics, 2019, 11; 359 [PMID: 31340601] [DOI:10.3390/pharmaceutics11070359] [PMCID: PMC6681070]
5. Jain KK, "Drug Delivery Systems". Methods Mol Biol 2008; 437:1-50. [PMID: 18369961] [DOI:10.1007/978-1-59745-210-6_1]
6. How TV, Guidoin R, Young S. K, Engineering design of vascular prostheses. proceedings of the institution of mechanical engineers. J Eng Med 1992; 206: 61-71. [PMID: 1466693] [DOI:10.1243/PIME_PROC_1992_206_269_02]
7. Fathi Azarbayjani A, Avizheh L, Peirouvi T, Diba K, Electrospun wound dressing as a promising tool for the therapeutic delivery of ascorbic acid and caffeine.Ther Deliv 2019; 10 (12): 757-767. [PMID: 31840563] [DOI:10.4155/tde-2019-0059]
8. Sivan M, Madheswaran D, Asadian M, Cools P, Thukkaram M, Van Der Voort P, et al, Plasma treatment effects on bulk properties of polycaprolactone nanofibrous mats fabricated by uncommon ac electrospinning: a comparative study. Surf Coat Technol 2020; 399: 126203. [URL:] [DOI:10.1016/j.surfcoat.2020.126203]
9. Garg K, Bowlin GL, Electrospinning Jets and Nanofibrous Structures. Biomicrofluidics 2011; 5(1): 013403. [PMID: 21522493] [DOI:10.1063/1.3567097] [PMCID: PMC3082340]
10. Kim KW, Lee KH, Khil MS, Ho YS, Kim HY, Effect of molecular weight and the linear velocity of drum surface on the properties of electrospun poly(ethylene terephthalate) nonwovens. Fiber Polym 2004; 5(2): 122-127. [URL:] [DOI:10.1007/BF02902925]
11. Dersch R, Liu T, Schaper AK, Greiner A, Wendorff JH, Electrospun nanofibers: internal structure and intrinsic orientation. J Polym Sci A Polym Chem 2003; 41(4): 545-553. [URL:] [DOI:10.1002/pola.10609]
12. Beachley V, Wen X, Effect of electrospinning parameters on the nanofiber diameter and length. Mater Sci Eng C Biomim Supramol Syst 2009; 29(3): 663-668. [PMID: 21461344] [DOI:10.1016/j.msec.2008.10.037] [PMCID: PMC3065832]
13. Leach MK, Feng ZQ, Tuck SJ, Corey JM, Electrospinning fundamentals: optimizing solution and apparatus parameters. J Vis Exp 2011; 47(47): e2494. [PMID: 21304466] [DOI:10.3791/2494-v] [PMCID: PMC3182658]
14. Zamani M, Prabhakaran MP, Ramakrishna S. Advances in drug delivery via electrospun and electrosprayed nanomaterials. Int J Nanomed 2013; 8: 2997-3017. [PMID: 23976851] [DOI:10.2147/IJN.S43575] [PMCID: PMC3746732]
15. Ranade VV, Drug delivery systems, 4.Implants in drug delivery. J Clin Pharmacol 1990; 30: 871-889. [PMID: 2229447] [DOI:10.1002/j.1552-4604.1990.tb03566.x]
16. Guarino V, Gentile G, Sorrentino L, Ambrosio L, Polycaprolactone: Synthesis, Properties and Applications. Encycl Polym Sci Technol. 2017; 1-36. [URL:] [DOI:10.1002/0471440264.pst658]
17. Nair LS, Laurencin CT, Biodegradable polymers as biomaterials. Prog Polym Sci 2007; 32: 762-798. [URL:] [DOI:10.1016/j.progpolymsci.2007.05.017]
18. Y Murai, T Ohta, H Tadaki, K Miyajima, M Shinohara, F Fatchiyah, et al. Assessment of Pharmacological Responses to an Anti-diabetic Drug in a New Obese Type 2 Diabetic Rat Model, Med Arch 2017; 71(6): 380-384. [PMID: 29416195] [DOI:10.5455/medarh.2017.71.380-384] [PMCID: PMC5764610]
19. Emin Cam M, Yildiz S, Alenezi1 H, Cesur S, Sinemcan Ozcan G, Erdemir G, et al. Evaluation of burst release and sustained release of pioglitazone-loaded fibrous mats on diabetic wound healing: an in vitro and in vivo comparison study. J R Soc Interface 2020; 17(162): 20190712. [PMID: 31964272] [DOI:10.1098/rsif.2019.0712] [PMCID: PMC7014808]
20. Umesh MB, Upendra CG, Pravin DC, Development of Pioglitazone hydrochloride liposhperes by melt dispersion technique: optimization and evaluation. J Appl Pharm Sci 2016; 6(01):107-117. [URL:] [DOI:10.7324/JAPS.2016.600118]
21. Uekusa T, Sugano K, Precipitation behavior of Pioglitazone on the particle surface of hydrochloride salt in biorelevant media. J Pharm Biomed Anal 2018;161: 45-50. [PMID: 30144628] [DOI:10.1016/j.jpba.2018.08.028]
22. Nair AB, Gupta S, Al-Dhubiab BE, Jacob S, Shinu P, Shah J, et al. Effective therapeutic delivery and bioavailability enhancement of pioglitazone using drug in adhesive transdermal patch, Pharmaceutics 2019; 11:359 [PMID: 31340601] [DOI:10.3390/pharmaceutics11070359] [PMCID: PMC6681070]
23. Gao Z, Wang Q, Yao Q, Zhang P, Application of electrospun nanofiber membrane in the treatment of diabetic wounds. Pharmaceutics 2022; 14:6. [PMID: 35056901] [DOI:10.3390/pharmaceutics14010006] [PMCID: PMC8780153]
24. Kamel R, El-batanony, Salama A, Pioglitazone-loaded three-dimensional composite polymeric scaffolds: A proof of concept study in wounded diabetic rats. Int J Pharm 2019;570: 118667. [PMID: 31494238] [DOI:10.1016/j.ijpharm.2019.118667]
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
